Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroparesis: early-phase trial registry
24 of 45 indexed Gastroparesis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #323 of 28,707 conditions by registered trial count.
45 US clinical trials · 24 currently recruiting · #323 of 28,707 conditions by registered trial count
Gastroparesis: 45 US clinical trials tracked, 24 recruiting.
Gastroparesis is the subject of 45 registered US clinical trials on ClinicalTrials.gov, 24 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Indiana University, running 7 of these trials.
Enrollment posture brief
Registry condition gastroparesis
OPEN 24 | RECR 53% | LATE 3 | EARLY 9 | RANK #323 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Advanced Lung Non-Small Cell Carcinoma (53% recruiting · 15 trials)
Gastroparesis lists 24 open slots (53% of 45 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroparesis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroparesis is recruiting above its size-band peers.
24 of 45 indexed trials (53.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gastroparesis research.
Indiana University accounts for 7 of 45 trials (15.6%). 30 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroparesis enrolment sits around 65 participants.
Median target enrolment is 65 among the 45 trials that report a genuine target (sentinel values excluded). 26 of those (57.8%) plan for fewer than 100 participants.
-
Gastroparesis splits between interventional and observational designs.
29 interventional and 16 observational studies make up this index (64.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
45 total, page 1 of 1
Indiana University Gastrointestinal Motility Diagnosis Registry
Indiana University
NCT04506593
Gastroparesis Outcome Longitudinal Database Enrolled Numerically
University of Louisville
NCT03876288
BSGM to Evaluate Patients With GI Symptoms
Children's Hospital of Philadelphia
NCT05880199
Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy for Gastrointestinal Motility Disorders
AdventHealth
NCT05905016
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
University of Louisville
NCT04208828
Different Doses of Naronapride Vs. Placebo in Gastroparesis
Dr. Falk Pharma
NCT05621811
GI Neuromuscular Pathology Prospective Registry
Indiana University
NCT02165059
Gastroparesis Registry 4
Johns Hopkins Bloomberg School of Public Health
NCT05846802
GpCRC Pediatric Gastroparesis Registry 2
Johns Hopkins Bloomberg School of Public Health
NCT05981300
Domperidone in Treating Patients With Gastrointestinal Disorders
M.D. Anderson Cancer Center
NCT01696734
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
Johns Hopkins Bloomberg School of Public Health
NCT04661215
Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis
Indiana University
NCT04434781
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
Massachusetts General Hospital
NCT03603730
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
Enterra Medical
NCT06560307
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
Enterra Medical
NCT05980455
Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes
Matthew Allemang
NCT04696159
Transpyloric Stenting As a Predictor for G-POEM for Refractory Gastroparesis
Northwestern University
NCT04287647
Study of Gastric Motility in Eosinophilic Gastritis
Children's Hospital Medical Center, Cincinnati
NCT05229432
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
Massachusetts General Hospital
NCT03531450
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
Indiana University
NCT06493032
Compassionate Use of Domperidone for Refractory Gastroparesis
Children's Mercy Hospital Kansas City
NCT04699591
TENS in Scleroderma
University of Michigan
NCT06646913
Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)
Wake Forest University Health Sciences
NCT06732453
Growth Hormone for the Treatment of Gastroparesis
Mayo Clinic
NCT06803589
Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve
Indiana University
NCT02159586
Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy
University of Colorado, Denver
NCT03626350
ABVN Phase 2-Studying the Effect of Stimulation on the Auricular Branch of the Vagal Nerve
Indiana University
NCT06491758
Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms Trial
Matthew Allemang
NCT05039424
Vagus Nerve Response in Gastroparesis Patients
Indiana University
NCT04207996
Magnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis
Indiana University School of Medicine
NCT04282317
Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility
University of California, Los Angeles
NCT05004012
Establishing a Pediatric Reference Range for the 13C-Spirulina Gastric Emptying Breath Test (GEBT)
Cairn Diagnostics
NCT06004596
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
Vanda Pharmaceuticals
NCT02970968
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
The SmartPill Corporation
NCT00128284
Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.
University of North Carolina, Chapel Hill
NCT06038734
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GlaxoSmithKline
NCT01262898
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
The Cleveland Clinic
NCT06533527
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
Adil Bharucha
NCT02232308
Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma
Johns Hopkins University
NCT03294616
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
Motus Therapeutics
NCT01394055
Sancuso® for Gastroparesis: An Open Label Study.
Temple University
NCT01989221
Pioglitazone for Idiopathic Gastroparesis
Johns Hopkins University
NCT04300127
Validation of Plant-Based Vegan Meal for Gastric Emptying Testing in 10 Healthy Subjects
Mayo Clinic
NCT06991036
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
Otsuka Pharmaceutical Co.
NCT01074710
Endoscopic Full Thickness Biopsy, Gastric Wall.
Mayo Clinic
NCT01650714
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroparesis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroparesis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroparesis page
45 registered trials, 24 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 24 Gastroparesis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Indiana University sponsors the most Gastroparesis trials on record, review their full trial history before evaluating a specific study. See Indiana University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroparesis condition card totals 45 registered trials; most-linked intervention Placebo; top US site state Indiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.